2023-03-31-accounts - Action Duchenne Limited

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

			Page
Administrative	and statutory details
Message I'rom the National Director			2-8
Report ofthe	Trustees		9 - 14
Independent	Auditors'	report	15- 18
Accounts comprising:
Statement of	financial	activities	19
Statement of	financial	position	20
Statement of	cashflows		21
Notes to the financial		statements	22-32

		ADMINISTRATIVE AND STATUTORY DETAILS	ADMINISTRATIVE AND STATUTORY DETAILS	ADMINISTRATIVE AND STATUTORY DETAILS
Board ofTrustees		Mark Silverman
		Gary Fegan
		Roger Cockerton	(Treasurer)
		Victoria Penrice
National Director		Florence Boulton
Scientific	Advisory Board	Dame Professor K		Davies —Chair
		Professor M Wood		—Vice Chair
Registered	oAice	Wellesley House
		Duke ofWellington		Avenue
		Royal Arsenal
		London
		SE]86SS
Auditors		Simpson Wreford	LLP
		Wellesley House
		Duke ofWellington		Avenue
		Royal Arsenal
		London
		SE186SS
Company	number	04899036
Charity number		1101971
		SC043852 (Scotland)
Solicitors		Morgan Cole
		Bradley Court
		Park Place
		Cardiff
		CF103DR
Banks		Barclays Bank
		PO Box3
		77North Street,
		Keighley
		BD213SA
		The Co-operative	Bank Pic
		POBox250
		Skelmersdale
		N3 6WT

			2023	2023	2023	2022
			Unresticted	Restricted	Total	Total
		Notes	funds	funds	funds	funds
Income and endowments	from:	4
Donations and legacies			]64,669	128,814	293,483	347,160
Charitable activities				257,442	257,442	98,960
Other trading activities			160,911		160,911	114,797
Investments			28		28	19
Other - Government grants						I 250
Total income			~325608	3~86256	7~11864	~562 186
Expenditure on:		16
Raising funds:
Cost ofevents and general	fundraising		35,725		35,725	75,320
Charitable activities:
Campaigning and education,			40,528	87,680	128,208	79,040
Research, supporting families,
and grants payable			153,057	227,596	380,653	173,887
Improved management and
medical care			36259		36259	31616
Total expenditure			~265569	315276	~580845	~359863
Net income/(expenditure)			60,039	70,980	131,019	202,323
Transfers between funds
Net movement in funds			~60039	~70980	~131019	202 323
Reconciliation offunds:
Balance at 1 April 2022			420 156	240	420 396	218073
Balance at 31March 2023

	Notes	Notes	2023		2022
Fixed assets
Tangible assets			2,161		2,881
Investments			2		2
			2,163		2,883
Current assets
Debtors		7	6,948	11,049
Cash at bank	and in hand	20	625039	475 928
			631,987	486,977
Current liabilities
Creditors due within one year			(~82 735	35 222
Net current	assets		549252		451 755
Total assets	less current liabilities		551,415		454,638
Creditors due more than one year		9			34.242
Net assets		15	~551415		~420396
Represented	by:
Resnicted funds		13	71,220		240
Unrestricted	funds	14	480 195		420 156
					~420396

				2023	2022
			Notes	Total	Total
Cashfloivs from operating	activities:
Net cash provided by operating activities			19	194066	88 454
Cashflows from investing	activities:
Dividends, interest, and rents from investments				28	19
Purchase ofequipment					(2,772)
Proceeds from disposal oftangibles
Net cash (used in) by investing activites				28	~2753)
Cashflows from financing	activities:
Loan received
Interest paid				(719)	(2,034)
Net cash (used in)/provided	by financing	activites		~44 264	~4486
Change in cash and cash equivalents in the reporting period				149,111	79,181
Cash and cash equivalents	as at 1 April 2022		20	475 928	396747
Cash and cash equivalents	as at 3 l March	2023	20	~2

Investments
			2023	2022
Programme	related investments
Convertible	loan note in Halo Therapeutics	LLC	225,000	225,000
Less: trcatcd	as grant paid 2012		~224 999	(~224 999
			I	I

2023	2022
f.

Other	investments
1,371	Ordinary shares	of	60.001

Cred	itors:	am	ounts faUing due after more than	one year
				2023	2022
					f
Bank	loans	and	overdrails		34242

		Unrestricted	Restricted	2023	2022
		funds	funds	Total	Total
Fixed assets		2,163		2,163	2,883
Current assets		543,802	88,185	631,987	486,977
Current liabilides		(65,770)	(16,965)	(82,735)	(35,222)
Non-current	liabilities				~34242

						2023	2022
Support costs:
Bank charges and interest						4,226	4,847
Insurance						1,364	1,020
Wages and salaries						294,999	227,559
Printing, postage and	stationery					6,282	7,251
Training, recruitment	and		other	staff costs		35,523	23,687
Rent and rates							240
Computer costs						19,550	12,029
Storage						2,561	2,501
Telephone and internet		costs				4,472	2,559
Depreciation Loss on disposal oftangibles						720	960 851
Trustees' meetings							3
Governance costs						20,446	14,753
Professional fees						17,600	13,834
Miscellaneous expenditure						7.102	4 065
							31 1
Support and governance			costs are allocated as follows:
					Support and	Direct
					governance	costs	Total
Research, supporting	families,			and
grants payable 56%					234,761	145,891	380,653
Fundraising and events		6.75%			28,002	7,723	35,725
Scientific education 28%					116,903	11,305	]28,208
improved management		and medical care 8%			35 179	1989	36259
					414848	168999	580 45

were	treated as grants payable during the year:
		2023	2022
Grant	—The University ofNewcastle		21,426
Grant	—Queen Mary University London		25,320
Grant	—World Duchenne Organisation

accounts:
							2023	2022
							E
Grant to The	University ofGlasgow						10590
							590
18.Reconciliation ofnet income				/ (expenditure)			to net cashflow from operating activities
							2023	2022
							Total	Total
Net surplus/(deficit)			for the reporting		period		131,019	202,323
Adjustments	for:
Depreciation	charges						720	960
Loss on disposal oftangibles								851
Interest payable							719	2,034
Grant income	related		to bounce	back loan				(1,250)
Dividends, interest,		and rents from investments					(28)	(19)
Increase / (decrease)			in debtors				4,101	18,612
Increase / (decrease)			in creditors				57535	(~135057
Net cash provided		by (used in) operating				activites		88454
19.Analysis of	cash and cash equivalents
							2023	2022
							K
Cash in hand							625 039	475 928
							~50	~4
							31